Reduced‐intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long‐term outcomes
Karl S. Peggs(Royal London Hospital), Álvaro Urbano-Ispizúa(University of St.Gallen), Anne Parker(Queen Elizabeth University Hospital), Jorge Sierra(Universitat Autònoma de Barcelona), Stephen Mackinnon(The Royal Free Hospital), Miguel Canales(Hospital Universitario La Paz), Guillermo Sanz(Instituto de Salud Carlos III), Premini Mahendra(University College Hospital), Iván Alvarez(Hospital de Sant Pau), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Ann Hunter(University Medical Center Freiburg), Josep‐María Ribera(Universitat Autònoma de Barcelona), Wendi Qian(MRC Clinical Trials Unit at UCL), Kirsty Thomson(University College Hospital), Anthony H. Goldstone(Royal London Hospital), James Cavet(The Christie NHS Foundation Trust), Donald Milligan(National Health Service), Reyes Arranz, Dolores Caballero(Complejo Hospitalario de Salamanca), David C. Linch(University of Oxford), J Garcı́a-Conde(Hospital de Sant Pau)
Cited by 106
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k